Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3252-3256

  Chan, Liana C ^a,b   Basuino, Li ^a   Dip, Etyene C ^a   Chambers, Henry F ^a  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; TEDIZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; AORTIC VALVE ENDOCARDITIS; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ENDOCARDITIS; COLONY FORMING UNIT; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EXPOSURE; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS ENDOCARDITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN BINDING; RABBIT MODEL; ANIMAL; DRUG ADMINISTRATION; DRUG EFFECTS; ENDOCARDITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; RABBIT; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG ADMINISTRATION SCHEDULE; ENDOCARDITIS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; ORGANOPHOSPHATES; OXAZOLES; RABBITS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84929579535     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04376-14     Document Type: Article

References (21)

1. Thomson KS, Goering RV. 2013. Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins. Antimicrob Agents Chemother 57:2892-2895. http://dx.doi.org/10.1128/AAC.00274-13.
2. Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D, Zurenko G. 2008. In vitro activity of TR-700, the anti-bacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 52:4442-4447. http://dx.doi.org/10.1128/AAC.00859-08.
3. Louie A, Liu W, Kulawy R, Drusano GL. 2011. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother 55:3453-3460. http://dx.doi.org/10.1128/AAC.01565-10.
4. Drusano GL, Liu W, Kulawy R, Louie A. 2011. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob Agents Chemother 55:5300-5305. http://dx.doi.org/10.1128/AAC.00502-11.
5. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed. M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Fuchs PC, Barry AL, Brown SD. 2000. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbiol Infect Dis 38:51-58. http://dx.doi.org/10.1016/S0732-8893(00)00164-4.
7. Garrison PK, Freedman LR. 1970. Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale J Biol Med 42:394-410.
8. Chambers HF. 2005. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycinintermediate Staphylococcus aureus. Antimicrob Agents Chemother 49:884-888. http://dx.doi.org/10.1128/AAC.49.3.884-888.2005.
9. Marco F, de la Maria CG, Armero Y, Amat E, Soy D, Moreno A, del Rio A, Almela M, Mestres CA, Gatell JM, Jimenez de Anta MT, Miro JM. 2008. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 52:2538-2543. http://dx.doi.org/10.1128/AAC.00510-07.
10. Tattevin P, Basuino L, Bauer D, Diep BA, Chambers HF. 2010. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:610-613. http://dx.doi.org/10.1128/AAC.00886-09.
11. Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, Prokocimer P. 2014. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos 42: 1275-1284. http://dx.doi.org/10.1124/dmd.113.056697.
12. Rybak JM, Marx K, Martin CA. 2014. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy 34:1198-1208. http://dx.doi.org/10.1002/phar.1491.
13. Flanagan SD, Bien PA, Munoz KA, Minassian SL, Prokocimer PG. 2014. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug. Pharmacotherapy 34:240-250. http://dx.doi.org/10.1002/phar.1337.
14. Sahre M, Sabarinath S, Grant M, Seubert C, Deanda C, Prokocimer P, Derendorf H. 2012. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents 40:51-54. http://dx.doi.org /10.1016/j.ijantimicag.2012.03.006.
15. Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Kuti JL, Nicolau DP. 2012. Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers. Antimicrob Agents Chemother 56:2627-2634. http://dx.doi.org/10.1128/AAC.05354-11.
16. Flanagan S, Bartizal K, Minassian SL, Fang E, Prokocimer P. 2013. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions. Antimicrob Agents Chemother 57: 3060-3066. http://dx.doi.org/10.1128/AAC.00431-13.
17. Lodise TP, Drusano GL. 2014. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin Infect Dis 58:(Suppl 1):S28-S34. http://dx.doi.org/10.1093/cid/cit615.
18. Lepak AJ, Marchillo K, Pichereau S, Craig WA, Andes DR. 2012. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model. Antimicrob Agents Chemother 56:5916-5922. http://dx.doi.org/10.1128/AAC.01303-12.
19. Flanagan S, Fang E, Munoz KA, Minassian SL, Prokocimer PG. 2014. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy 34:891-900. http://dx.doi.org/10.1002/phar.1458.
20. Oramas-Shirey MP, Buchanan LV, Dileto-Fang CL, Dailey CF, Ford CW, Batts DH, Gibson JK. 2001. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 47:349-352. http://dx.doi.org/10.1093/jac/47.3.349.
21. Dailey CF, Dileto-Fang CL, Buchanan LV, Oramas-Shirey MP, Batts DH, Ford CW, Gibson JK. 2001. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 45:2304-2308. http://dx.doi.org/10.1128/AAC.45.8.2304-2308.2001.